D6900C00003: A Phase III Randomized Open Label Multicenter Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician�s Choice of Chemotherapy in Participants with B7 H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti PD 1/Anti PD L1 Therapy (BLUESTAR Endometrial01)
